Elecsys® ProGRP

Accurate information for differential diagnosis in lung cancer

  • Lung cancer is one of the most common cancers in the world with 1.35 million new cases diagnosed every year
  • The two main histological types of the disease are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It is important to distinguish between these two subtypes as they have different treatments and prognoses
  • NSCLC (approx. 80% of cases) is curable with surgery in the early stages. SCLC, however, is an aggressively spreading neoplasm of rapid growth that is usually only treatable with chemo- and radiotherapy
  • Pro-gastrin releasing peptide (ProGRP) is a novel tumor marker with benefits for lung cancer patient management. It is the tumor marker of choice for SCLC as it supports quick and accurate discrimination between SCLC and NSCLC for a faster decision on patient treatment
  • ProGRP can also be used to assess response to therapy and monitor recurrence of the disease

The 85.7 pg/mL cut-off value is based on a 95 % specificity from the NSCLC aollective.

Assay time
18 min
Sample material
Serum collected using standard sampling tubes or tubes containing separating gel
Li-heparin plasma, K2-EDTA and K3-EDTA plasma
Sample volume
30 μL
Detection Limit* LoD 3 pg/mL, LoQ 3.99 pg/mL
Measuring Range 3 - 5,000 pg/mL

*LoD = Limit of Detection; LoQ = Limit of Quantitation (≤ 30 % total error).

A tumor marker for the differential diagnosis of lung cancer

elecsys calcitonin figure1

fig 1

The marker for SCLC

  • High discrimination between SCLC and NSCLC/other malignancies/benign diseases (figure 1)
  • Further increase in sensitivity when combined with NSE
  • Recommended by the NACB for differential diagnosis, post-operative surveillance, monitoring therapy in advanced disease and detection of recurrent disease
elecsys calcitonin table1

table 1

ECL technology for reliable performance

  • Higher sensitivity and specificity for better discrimination between SCLC and NSCLC (table 1)
  • Excellent precision across the entire measuring range for reliable results

elecsys calcitonin figure2

fig 2

  • Equivalent performance between serum and plasma (figure 2) allowing ProGRP and NSE to be tested from one tube (NSE is not suitable for use with plasma due to nature of analyte)

Increased efficiency and consistency of results

  • Lung cancer testing on one automated platform – CEA, CYFRA 21-1, NSE and ProGRP
  • Consolidation with the leading and committed portfolio of tumor markers from Roche – PSA, fPSA, Ferritin, HCB+b, AFP, Calcitonin, Tg, CA19-9, CA125, CA15-3, CA72-4, S100, HE4
  • Consistent results across cobas serum work area platforms – automated platforms for every lab size

Booklet of key publication abstracts regarding the role of ProGRP in the differential diagnosis in lung cancer and the management of small cell lung cancer patients. Download

Shibayama, T., Ueoka, H., NishiiI, K., et al. (2001). Complementary roles of pro-gastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung cancer 32, 61 – 69

Stieber, P., Hatz, R., et al. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer. NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic, Lung Cancer (Section 3P)